May 04, 2020: At the beginning of April, the Austrian company APEIRON Biologics AG announced that it has initiated a Phase II clinical trial of APN01 in Austria, Germany and Denmark to treat COVID-19. APN01 is the recombinant form of the human angiotensin-converting enzyme 2 (rhACE2), which has the potential to block the infection of cells by the novel SARS-CoV-2 virus. The clinical trial will treat 200 severely infected COVID-19 patients. From many competitors, VelaLabs was selected to support the analysis of the patient samples of the study. In short time frames six samples will be taken from every patient and tested immediately at the VelaLabs facilities. This summer (2020), the evaluation is expected to be finalized at latest.The team of VelaLabs is proud to be a part of the world-wide fight against the SARS-CoV-2 pandemic.
For further information please follow these links:
If you have any questions or concerns, please contact us via email firstname.lastname@example.org or give us a phone call at +43 189 059 7911.